Cytosystems

About:

Cytosystems is a pathology company that develops non-invasive cancer diagnostic and stratification technologies for bladder cancer.

Website: http://www.cytosystems.com

Top Investors: EASME - EU Executive Agency for SMEs, Aurora Private Equity

Description:

Cytosystems is a pathology company that develops non-invasive cancer diagnostic and stratification technologies for initially for the management of bladder cancer. The company’s first product, BladderLight™, is an integrated and automated digital pathology solution using a big data systems approach for the diagnosis and monitoring of bladder cancer. Cytosystems has developed two patent-pending technologies: a point of care cell collection device which optimizes analyte quality at point of patient care and the use of artificial intelligence pattern recognition software to interrogate and objectively classify individual urothelial cells as cancer positive or negative. This whole-cell approach can help with clinical decision making and provides a highly sensitive and specific test which achieves the challenging performance levels demanded of a non-invasive test by patients and clinicians.